Dare Bioscience (DARE) Competitors $2.42 +0.02 (+0.83%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.37 -0.05 (-2.07%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. ADAP, VIRI, WHWK, VXRT, MGX, VTGN, ORMP, ARTV, XBIT, and ENTXShould you be buying Dare Bioscience stock or one of its competitors? The main competitors of Dare Bioscience include Adaptimmune Therapeutics (ADAP), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Vaxart (VXRT), Metagenomi (MGX), VistaGen Therapeutics (VTGN), Oramed Pharmaceuticals (ORMP), Artiva Biotherapeutics (ARTV), XBiotech (XBIT), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. Dare Bioscience vs. Its Competitors Adaptimmune Therapeutics Virios Therapeutics Whitehawk Therapeutics Vaxart Metagenomi VistaGen Therapeutics Oramed Pharmaceuticals Artiva Biotherapeutics XBiotech Entera Bio Adaptimmune Therapeutics (NASDAQ:ADAP) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Which has higher valuation & earnings, ADAP or DARE? Dare Bioscience has lower revenue, but higher earnings than Adaptimmune Therapeutics. Dare Bioscience is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$178.03M0.12-$70.81M-$0.27-0.30Dare Bioscience$10K2,185.26-$4.05M-$0.17-14.24 Does the media refer more to ADAP or DARE? In the previous week, Adaptimmune Therapeutics had 13 more articles in the media than Dare Bioscience. MarketBeat recorded 17 mentions for Adaptimmune Therapeutics and 4 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.72 beat Adaptimmune Therapeutics' score of -0.66 indicating that Dare Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptimmune Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Negative Dare Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in ADAP or DARE? 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 12.7% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 4.0% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, ADAP or DARE? Adaptimmune Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Do analysts prefer ADAP or DARE? Adaptimmune Therapeutics presently has a consensus target price of $1.35, indicating a potential upside of 1,591.70%. Dare Bioscience has a consensus target price of $12.00, indicating a potential upside of 395.87%. Given Adaptimmune Therapeutics' higher possible upside, equities research analysts clearly believe Adaptimmune Therapeutics is more favorable than Dare Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ADAP or DARE more profitable? Dare Bioscience has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -38.91%. Dare Bioscience's return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-38.91% -163.73% -23.65% Dare Bioscience N/A N/A -8.14% SummaryDare Bioscience beats Adaptimmune Therapeutics on 8 of the 15 factors compared between the two stocks. Get Dare Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDare BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.67M$3.00B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-14.2317.7428.8323.83Price / Sales2,185.26179.21372.0766.02Price / CashN/A41.9535.4557.96Price / Book-3.518.508.275.54Net Income-$4.05M-$55.06M$3.25B$259.28M7 Day Performance-5.84%-3.99%-3.73%-4.68%1 Month Performance0.83%9.58%4.29%4.36%1 Year Performance-27.11%6.70%25.87%17.88% Dare Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDare Bioscience1.751 of 5 stars$2.42+0.8%$12.00+395.9%-29.0%$21.67M$10K-14.2330Short Interest ↑ADAPAdaptimmune Therapeutics2.4959 of 5 stars$0.10-71.2%$1.35+1,251.7%-93.7%$91.95M$178.03M-0.37490News CoverageAnalyst DowngradeAnalyst RevisionGap UpHigh Trading VolumeVIRIVirios TherapeuticsN/A$4.77+0.8%$5.00+4.8%+2,247.1%$91.86MN/A-17.675Upcoming EarningsWHWKWhitehawk TherapeuticsN/A$1.81-7.2%N/AN/A$91.86M$25.98M11.3140Gap UpVXRTVaxart3.3279 of 5 stars$0.41+1.3%$3.00+640.7%-46.0%$91.57M$47.40M-1.50120News CoveragePositive NewsMGXMetagenomi2.4384 of 5 stars$2.52+3.7%$13.00+415.9%-35.7%$90.84M$52.29M-1.19236VTGNVistaGen Therapeutics1.0288 of 5 stars$3.19+3.6%N/A-13.2%$89.81M$490K-1.9240News CoverageGap UpHigh Trading VolumeORMPOramed Pharmaceuticals0.5957 of 5 stars$2.21+2.3%N/A-10.5%$88.22M$1.34M-5.0210News CoverageAnalyst RevisionARTVArtiva Biotherapeutics2.1345 of 5 stars$2.96-17.8%$17.80+501.4%-75.6%$87.71M$250K0.0081News CoverageUpcoming EarningsXBITXBiotech0.992 of 5 stars$2.82-1.7%N/A-61.0%$87.50M$4.01M-2.19100News CoveragePositive NewsShort Interest ↑ENTXEntera Bio2.6232 of 5 stars$2.06+10.8%$10.00+385.4%+21.1%$84.54M$180K-7.9220News CoveragePositive NewsUpcoming EarningsGap UpHigh Trading Volume Related Companies and Tools Related Companies Adaptimmune Therapeutics Alternatives Virios Therapeutics Alternatives Whitehawk Therapeutics Alternatives Vaxart Alternatives Metagenomi Alternatives VistaGen Therapeutics Alternatives Oramed Pharmaceuticals Alternatives Artiva Biotherapeutics Alternatives XBiotech Alternatives Entera Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
